Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun;56(6):3047-53.
doi: 10.1128/AAC.06460-11. Epub 2012 Apr 2.

Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis

Collaborators, Affiliations

Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis

Lukas Fenner et al. Antimicrob Agents Chemother. 2012 Jun.

Abstract

Bacterial factors may contribute to the global emergence and spread of drug-resistant tuberculosis (TB). Only a few studies have reported on the interactions between different bacterial factors. We studied drug-resistant Mycobacterium tuberculosis isolates from a nationwide study conducted from 2000 to 2008 in Switzerland. We determined quantitative drug resistance levels of first-line drugs by using Bactec MGIT-960 and drug resistance genotypes by sequencing the hot-spot regions of the relevant genes. We determined recent transmission by molecular methods and collected clinical data. Overall, we analyzed 158 isolates that were resistant to isoniazid, rifampin, or ethambutol, 48 (30.4%) of which were multidrug resistant. Among 154 isoniazid-resistant strains, katG mutations were associated with high-level and inhA promoter mutations with low-level drug resistance. Only katG(S315T) (65.6% of all isoniazid-resistant strains) and inhA promoter -15C/T (22.7%) were found in molecular clusters. M. tuberculosis lineage 2 (includes Beijing genotype) was associated with any drug resistance (adjusted odds ratio [OR], 3.0; 95% confidence interval [CI], 1.7 to 5.6; P < 0.0001). Lineage 1 was associated with inhA promoter -15C/T mutations (OR, 6.4; 95% CI, 2.0 to 20.7; P = 0.002). We found that the genetic strain background influences the level of isoniazid resistance conveyed by particular mutations (interaction tests of drug resistance mutations across all lineages; P < 0.0001). In conclusion, M. tuberculosis drug resistance mutations were associated with various levels of drug resistance and transmission, and M. tuberculosis lineages were associated with particular drug resistance-conferring mutations and phenotypic drug resistance. Our study also supports a role for epistatic interactions between different drug resistance mutations and strain genetic backgrounds in M. tuberculosis drug resistance.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Association between drug resistance level and drug resistance-conferring mutations among isoniazid drug-resistant Mycobacterium tuberculosis strains. Each mutation category was compared to all other categories; low-level drug resistance (<1 μg/ml) is the reference. P values of linear tests for trend are shown. The category “katG 315 mutations” includes mixed katG/inhA promoter mutants (10 strains) and katG double mutants (3 strains).
Fig 2
Fig 2
Distribution of main Mycobacterium tuberculosis lineages and semiquantitative drug susceptibility testing results (μg/ml) among isoniazid-resistant M. tuberculosis strains by drug resistance-conferring mutations. Numbers in bars indicate absolute numbers of strains. Lineage 1, Indo-Oceanic lineage; lineage 2, East Asian lineage (includes Beijing strains); lineage 3, CAS/Delhi; lineage 4, Euro-American lineage; other lineages, other lineages including West African lineages.

Similar articles

Cited by

References

    1. Baker L, Brown T, Maiden MC, Drobniewski F. 2004. Silent nucleotide polymorphisms and a phylogeny for Mycobacterium tuberculosis. Emerg. Infect. Dis. 10:1568–1577 - PMC - PubMed
    1. Blumberg HM, et al. 2003. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603–662 - PubMed
    1. Borrell S, Gagneux S. 2009. Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 13:1456–1466 - PubMed
    1. Borrell S, Gagneux S. 2011. Strain diversity, epistasis and the evolution of drug resistance in Mycobacterium tuberculosis. Clin. Microbiol. Infect. 17:815–820 - PMC - PubMed
    1. Böttger EC. 2011. The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin. Microbiol. Infect. 17:1128–1134 - PubMed

Publication types

MeSH terms

LinkOut - more resources